Doseresponsible relationship of a point-of-care PT/INR to the novel factor Xa inhibitor DX9065a in patients with coronary artery disease: Results from XaNADU Phase 1B - Dyke, CK; Becker, RC; Bovill, EG (Thromb Haemost Suppl, 2001)
Abstract CD3614..